Subscribe

Your FREE subscription will give you access to articles, research reports, Biopharma CEO Confidence quarterly reports and much more!

Corporate Development

  • Portfolio Prioritization – Oncology

    Jun 11, 2018
    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus. 

     

    Read More »

  • Commercial Assessment

    Apr 27, 2018
    Situation: A mid-sized biotech company evaluating their Phase II Metabolic asset requested that Kineticos provide a commercial and financial assessment

     

    Read More »

  • Business Development and Licensing

    Feb 26, 2018
    Situation: A publicly traded pharmaceutical company seeking a strategic partner for their IND-ready asset was in need of support with

     

    Read More »

  • Tradeoff Analysis and Valuation

    Mar 16, 2017
    Situation: A preclinical precision medicine biotech company, looking to leverage their genome editing platform technology, was seeking support in narrowing

     

    Read More »

  • Biosimilar Commercial Assessment

    Mar 06, 2017
    Situation:  A multinational pharmaceutical company with broad manufacturing capabilities was considering horizontally expanding their portfolio to include biosimilars. Kineticos was

     

    Read More »

  • Business Model Analysis

    Mar 06, 2017
    Situation: A mid-size pharmaceutical company was losing market share and considering withdrawing sales support for one of their products. Due

     

    Read More »

  • Business Modeling

    Mar 06, 2017
    Situation: A publicly traded pharmaceutical company looking to bolster their existing portfolio asked Kineticos to provide them with a comparative

     

    Read More »

  • Key Opinion Leader Engagement

    Mar 06, 2017
    Situation: An emerging oncology company with a novel technology requested Kineticos’ support with establishing a development path for their clinically

     

    Read More »

  • Scientific Advisory Board Support

    Mar 06, 2017
    Situation: A publically traded pharmaceutical company with a stagnant Phase II ready PDE4 inhibitor asset required support to determine a

     

    Read More »

  • Tradeoff Analysis

    Mar 05, 2017
    Situation: A publicly traded pharmaceutical company with a stagnant Phase II ready PDE4 inhibitor asset required support to determine a

     

    Read More »

Top